<!DOCTYPE html
  PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:n1="urn:hl7-org:v3">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1">
   
      <title>Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer</title><style type="text/css">
body {
	color: rgb(26, 26, 26);
	background-color: rgb(255,255,255);
	font-family: Verdana, Tahoma, sans-serif;
	font-size: 11px;
}

a {
	color: rgb(0, 0, 255);
	background-color: rgb(255,255,255);
}

h1 {
	font-size: 12pt;
	font-weight: bold;
}

h2 {
	font-size: 11pt;
	font-weight: bold;
}

h3 {
	font-size: 10pt;
	font-weight: bold;
}

h4 {
	font-size: 8pt;
	font-weight: bold;
}

div {
	width: 80%;
}

table {
	line-height: 10pt;
	width: 80%;
}

tr {
	background-color: rgb(224,224,224);
}

td {
	padding: 0.1cm 0.2cm;
	vertical-align: top;
}

.h1center {
	font-size: 12pt;
	font-weight: bold;
	text-align: center;
	width: 80%;
}

.header_table{
	border: 1pt inset rgb(0,0,0);
}

.narr_table {
	width: 100%;
}

.narr_tr {
	background-color: rgb(225,225,225);
}
pre {
 overflow: auto; /* Use horizontal scroller if needed; for Firefox 2, not needed in Firefox 3 */
 white-space: pre-wrap; /* css-3 */
 white-space: -moz-pre-wrap !important; /* Mozilla, since 1999 */
 white-space: -pre-wrap; /* Opera 4-6 */
 white-space: -o-pre-wrap; /* Opera 7 */
 word-wrap: break-word; /* Internet Explorer 5.5+ */
 font-family: Verdana, Tahoma, sans-serif;
 font-size: 11px;
 text-align:left;
 margin: 0px 0px 0px 0px;
 padding:0px 0px 0px 0px;
}
.narr_th {
	background-color: rgb(201,201,201);
}

.td_label{
	font-weight: bold;
	color: white;
}
	</style></head>
   <body>
      <table class="header_table">
         <tbody>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">eMeasure Title</span></td>
               <td width="80%" colspan="3">Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">eMeasure Identifier<br>(Measure Authoring Tool)</span></td>
               <td width="30%">140</td>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">eMeasure Version number</span></td>
               <td width="30%">1</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">NQF Number</span></td>
               <td width="30%">0387</td>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">GUID</span></td>
               <td> ac639794-cb3f-4f4f-8fa6-680300d5ed4e</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measurement Period</span></td>
               <td width="80%" colspan="3">January 1, 20xx  through December 31, 20xx </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Steward</span></td>
               <td width="80%" colspan="3">American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Developer</span></td>
               <td width="80%" colspan="3">American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Endorsed By</span></td>
               <td width="80%" colspan="3">National Quality Forum</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Description</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Copyright</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Copyright 2012 American Medical Association, American Society of Clinical Oncology, and National Comprehensive Cancer Network. All Rights Reserved.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Disclaimer</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Physician Performance Measures (Measures) and related data specifications have been developed by the American Medical Association (AMA) - convened Physician Consortium for Performance Improvement(R) (the PCPI[TM]), American Society of Clinical Oncology, and National Comprehensive Cancer Network. These Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the AMA, (on behalf of the PCPI) or American Society of Clinical Oncology or National Comprehensive Cancer Network. Neither the AMA, American Society of Clinical Oncology, National Comprehensive Cancer Network, PCPI nor its members shall be responsible for any use of the Measures. 

THE MEASURES AND SPECIFICATIONS ARE PROVIDED &#8220;AS IS&#8221; WITHOUT WARRANTY OF ANY KIND. 

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, American Society of Clinical Oncology, National Comprehensive Cancer Network, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT[R]) or other coding contained in the specifications. 

CPT(R) contained in the Measure specifications is copyright 2004-2011 American Medical Association. LOINC(R) copyright 2004-2011 Regenstrief Institute, Inc. 

This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2011 International Health Terminology Standards Development Organisation. ICD-10 copyright 2011 World Health Organization. All Rights Reserved.

Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Scoring</span></td>
               <td width="80%" colspan="3">Proportion</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Type</span></td>
               <td width="80%" colspan="3">Process</td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Stratification</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>None</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Risk Adjustment</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>None</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Rate Aggregation</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>None</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Rationale</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Despite evidence suggesting the role of adjuvant endocrine therapy in lowering the risk of tumor recurrence, many female patients who should be receiving this therapy are not. 

This measure assesses whether patients with a certain stage of breast cancer (IC through IIIC) and ER/PR+ are currently receiving the therapy. 

There are allowable medical, patient, and system reasons to document instances in which a woman with stage IC through IIIC, ER/PR+ may not be a candidate for the therapy.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Clinical Recommendation Statement</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Adjuvant therapy for postmenopausal women with hormone receptor&#8211;positive breast cancer should include an aromatase inhibitor in order to lower the risk of tumor recurrence. Aromatase inhibitors are appropriate as initial treatment for women with contraindications to tamoxifen. For all other postmenopausal women, treatment options include 5 years of aromatase inhibitors treatment or sequential therapy consisting of tamoxifen (for either 2 to 3 years or 5 years) followed by aromatase inhibitors for 2 to 3, or 5 years (ASCO guidelines include narrative rankings) (ASCO). 

Patients intolerant of aromatase inhibitors should receive tamoxifen. Women with hormone receptor&#8211;negative tumors should not receive adjuvant endocrine therapy (ASCO guidelines include narrative rankings) (ASCO). 

Patients with invasive breast cancers that are estrogen or progesterone receptor positive should be considered for adjuvant endocrine therapy regardless of patient age, lymph node status, or whether or not adjuvant chemotherapy is to be administered (Category 2A) (NCCN). 

The most firmly established adjuvant endocrine therapy is tamoxifen for both premenopausal and postmenopausal women. Prospective, randomized trials demonstrate that the optimal duration of tamoxifen appears to be five years. In patients receiving both tamoxifen and chemotherapy, chemotherapy should be given first, followed by sequential tamoxifen. Several studies have evaluated aromatase inhibitors in the treatment of postmenopausal women with early-stage breast cancer (Category 2A) (NCCN).</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Improvement Notation</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Higher score indicates better quality</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Reference</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20;23(3):619-29. Available at: http://www.asco.org.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Reference</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1, 2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Definition</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>None</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Guidance</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>The denominator for this measure has been limited to patients with a first recorded breast cancer diagnosis within the past 5 years. The numerator captures patients who are prescribed adjuvant tamoxifen or AI, or received adjuvant tamoxifen or AI during the 12 month period. Date of breast cancer diagnosis is defined as date of pathologic diagnosis.</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Transmission Format</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>TBD</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Initial Patient Population</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>All female patients aged 18 years and older with a diagnosis of breast cancer</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Denominator</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Equals Initial Patient Population with stage IC through IIIC, estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Denominator Exclusions</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>None</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Numerator</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Patients who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Numerator Exclusions</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Not Applicable</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Denominator Exceptions</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>- Documentation of medical reason(s) for not prescribing tamoxifen or aromatase inhibitor (e.g., patient&#8217;s disease has progressed to metastatic, patient is receiving a gonadotropin-releasing hormone analogue, patient has received oophorectomy, patient is receiving radiation or chemotherapy, patient&#8217;s diagnosis date was &gt;= 5 years from reporting date, other medical reason)
- Documentation of patient reason(s) for not prescribing tamoxifen or aromatase inhibitor (e.g., patient refusal, other patient reasons)
- Documentation of system reason(s) for not prescribing tamoxifen or aromatase inhibitor (e.g., patient is currently enrolled in a clinical trial, other system reasons)</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Population</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Not Applicable</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Observations</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>Not Applicable</pre></div>
               </td>
            </tr>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Supplemental Data Elements</span></td>
               <td width="80%" colspan="3">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto"><pre>For every patient evaluated by this measure also identify payer, race, ethnicity and sex.</pre></div>
               </td>
            </tr>
         </tbody>
      </table>
      <h2><a name="toc">Table of Contents</a></h2>
      <ul>
         <li><a href="#d2530824e475">Population criteria</a></li>
         <li><a href="#d2530824e3146">Data criteria (QDM Data Elements)</a></li>
         <li><a href="#d2530824e4254">Reporting Stratification</a></li>
         <li><a href="#d2530824e4275">Supplemental Data Elements</a></li>
      </ul>
      <hr align="left" color="teal" size="2" width="80%">
      <h3><a name="d2530824e475" href="#toc">Population criteria</a></h3>
      <div>
         
         <ul>
            <li>
               <b>Initial Patient Population =</b>
               
               <ul>
                  <li>AND:  FIRST: "Occurrence A of Diagnosis, Active: Breast Cancer"  &lt;= 5 year(s) starts before or during 
                     <ul>
                        <li>OR: "Occurrence A of Encounter, Performed: Office Visit"</li>
                        <li>OR: "Occurrence A of Encounter, Performed: Face-to-Face Interaction"</li>
                        <li> during "Measurement Period"</li>
                     </ul>
                     
                  </li>
                  <li>AND: "Patient Characteristic Birthdate: birth date"  &gt;= 18 year(s) starts before start of "Measurement Period"</li>
                  <li>AND: Count &gt;= 2  of:
                     <ul>
                        <li>OR: "Occurrence A of Encounter, Performed: Office Visit"</li>
                        <li>OR: "Occurrence A of Encounter, Performed: Patient Provider Interaction"</li>
                        <li> during "Measurement Period"</li>
                     </ul>
                     
                  </li>
                  <li>AND: "Patient Characteristic Sex: Female"</li>
               </ul>
               
            </li>
            <li>
               <b>Denominator =</b>
               
               <ul>
                  <li>AND: "Initial Patient Population"</li>
                  <li>AND NOT: "Occurrence A of Procedure, Performed: Clinical Staging Procedure" starts before start of "Occurrence A of Diagnosis,
                     Active: Breast Cancer"
                  </li>
                  <li>AND: "Diagnosis, Active: Breast Cancer ER or PR Positive" starts after start of "Occurrence A of Diagnosis, Active: Breast
                     Cancer"
                  </li>
                  <li>AND: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Distant Metastasis Status M0')" starts
                     before or during 
                     <ul>
                        <li>OR: "Occurrence A of Encounter, Performed: Office Visit"</li>
                        <li>OR: "Occurrence A of Encounter, Performed: Face-to-Face Interaction"</li>
                     </ul>
                     
                  </li>
                  <li>AND: 
                     <ul>
                        <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Regional Lymph Node Status N3')"</li>
                        <li>OR: 
                           <ul>
                              <li>AND: 
                                 <ul>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Primary Tumor Size T0')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Primary Tumor Size T1')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Primary Tumor Size T1a')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Primary Tumor Size T1b')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Primary Tumor Size T1c')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Primary Tumor Size T1mi')"</li>
                                 </ul>
                                 
                              </li>
                              <li>AND: 
                                 <ul>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Regional Lymph Node Status N1')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Regional Lymph Node Status pN1a')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Regional Lymph Node Status pN1b')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Regional Lymph Node Status pN1c')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Regional Lymph Node Status pN1mi')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Regional Lymph Node Status N2')"</li>
                                 </ul>
                                 
                              </li>
                           </ul>
                           
                        </li>
                        <li>OR: 
                           <ul>
                              <li>AND: 
                                 <ul>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Primary Tumor Size T2')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Primary Tumor Size T3')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Primary Tumor Size T4')"</li>
                                 </ul>
                                 
                              </li>
                              <li>AND: 
                                 <ul>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Regional Lymph Node Status N0')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Regional Lymph Node Status N1')"</li>
                                    <li>OR: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Regional Lymph Node Status N2')"</li>
                                 </ul>
                                 
                              </li>
                           </ul>
                           
                        </li>
                        <li>OR: 
                           <ul>
                              <li>AND: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Primary Tumor Size T1c')"</li>
                              <li>AND: "Occurrence A of Procedure, Performed: Clinical Staging Procedure (result: 'Breast Cancer Regional Lymph Node Status
                                 N0')"
                              </li>
                           </ul>
                           
                        </li>
                     </ul>
                     
                  </li>
               </ul>
               
            </li>
            <li>
               <b>Denominator Exclusions =</b>
               
               <ul>
                  <li>None</li>
               </ul>
               
            </li>
            <li>
               <b>Numerator =</b>
               
               <ul>
                  <li>AND: 
                     <ul>
                        <li>OR: "Medication, Order: Tamoxifen or Aromatase Inhibitor Therapy" during 
                           <ul>
                              <li>OR: "Occurrence A of Encounter, Performed: Office Visit"</li>
                              <li>OR: "Occurrence A of Encounter, Performed: Face-to-Face Interaction"</li>
                           </ul>
                           
                        </li>
                        <li>OR: 
                           <ul>
                              <li>AND NOT: "Occurrence A of Medication, Active: Tamoxifen or Aromatase Inhibitor Therapy" ends before start of "Occurrence A
                                 of Encounter, Performed: Office Visit"
                              </li>
                              <li>AND: "Occurrence A of Medication, Active: Tamoxifen or Aromatase Inhibitor Therapy" starts before or during "Occurrence A
                                 of Encounter, Performed: Office Visit"
                              </li>
                           </ul>
                           
                        </li>
                        <li>OR: 
                           <ul>
                              <li>AND NOT: "Occurrence A of Medication, Active: Tamoxifen or Aromatase Inhibitor Therapy" ends before start of "Occurrence A
                                 of Encounter, Performed: Face-to-Face Interaction"
                              </li>
                              <li>AND: "Occurrence A of Medication, Active: Tamoxifen or Aromatase Inhibitor Therapy" starts before or during "Occurrence A
                                 of Encounter, Performed: Face-to-Face Interaction"
                              </li>
                           </ul>
                           
                        </li>
                     </ul>
                     
                  </li>
               </ul>
               
            </li>
            <li>
               <b>Denominator Exceptions =</b>
               
               <ul>
                  <li>AND: 
                     <ul>
                        <li>OR: 
                           <ul>
                              <li>OR: "Procedure, Performed: Radiation Therapy II"</li>
                              <li>OR: "Procedure, Performed: Chemotherapy"</li>
                              <li> during "Measurement Period"</li>
                           </ul>
                           
                        </li>
                        <li>OR: 
                           <ul>
                              <li>OR: "Medication, Order not done: Medical Reason" for "Tamoxifen or Aromatase Inhibitor Therapy Grouping Value Set"</li>
                              <li>OR: "Medication, Order not done: Patient Reason" for "Tamoxifen or Aromatase Inhibitor Therapy Grouping Value Set"</li>
                              <li>OR: "Medication, Intolerance: Tamoxifen or Aromatase Inhibitor Therapy"</li>
                              <li>OR: "Diagnosis, Active: Intolerance to Tamoxifen or Aromatase Inhibitor Therapy"</li>
                              <li>OR: "Medication, Active: Gonadotropin-releasing hormone analogue medication"</li>
                              <li>OR: "Procedure, Performed: Bilateral Oophorectomy"</li>
                              <li>OR: "Diagnosis, Active: Metastatic Sites Common to Breast Cancer"</li>
                              <li>OR: "Patient Characteristic Clinical Trial Participant: Clinical Trial Participant"</li>
                              <li>OR: "Medication, Order not done: System Reason" for "Tamoxifen or Aromatase Inhibitor Therapy Grouping Value Set"</li>
                              <li>OR: "Medication, Allergy: Tamoxifen or Aromatase Inhibitor Therapy"</li>
                              <li>OR: "Diagnosis, Active: Allergy to Tamoxifen or Aromatase Inhibitor Therapy"</li>
                              <li> starts before or during 
                                 <ul>
                                    <li>OR: "Occurrence A of Encounter, Performed: Office Visit"</li>
                                    <li>OR: "Occurrence A of Encounter, Performed: Face-to-Face Interaction"</li>
                                 </ul>
                                 
                              </li>
                           </ul>
                           
                        </li>
                     </ul>
                     
                  </li>
               </ul>
               
            </li>
         </ul>
         
      </div>
      <h3><a name="d2530824e3146" href="#toc">Data criteria (QDM Data Elements)</a></h3>
      <div>
         
         <ul>
            <li>
               "Diagnosis, Active: Allergy to Tamoxifen or Aromatase Inhibitor Therapy" using "Allergy to Tamoxifen or Aromatase Inhibitor Therapy Grouping Value Set (2.16.840.1.113883.3.526.3.1317)"
            </li>
            <li>
               "Diagnosis, Active: Breast Cancer" using "Breast Cancer Grouping Value Set (2.16.840.1.113883.3.526.3.389)"
            </li>
            <li>
               "Diagnosis, Active: Breast Cancer ER or PR Positive" using "Breast Cancer ER or PR Positive Grouping Value Set (2.16.840.1.113883.3.526.3.1303)"
            </li>
            <li>
               "Diagnosis, Active: Intolerance to Tamoxifen or Aromatase Inhibitor Therapy" using "Intolerance to Tamoxifen or Aromatase Inhibitor Therapy Grouping Value Set (2.16.840.1.113883.3.526.3.1318)"
            </li>
            <li>
               "Diagnosis, Active: Metastatic Sites Common to Breast Cancer" using "Metastatic Sites Common to Breast Cancer Grouping Value Set (2.16.840.1.113883.3.526.3.447)"
            </li>
            <li>
               "Encounter, Performed: Face-to-Face Interaction" using "Face-to-Face Interaction Grouping Value Set (2.16.840.1.113883.3.464.1003.101.12.1048)"
            </li>
            <li>
               "Encounter, Performed: Office Visit" using "Office Visit Grouping Value Set (2.16.840.1.113883.3.464.1003.101.12.1001)"
            </li>
            <li>
               "Encounter, Performed: Patient Provider Interaction" using "Patient Provider Interaction Grouping Value Set (2.16.840.1.113883.3.526.3.1012)"
            </li>
            <li>
               "Medication, Active: Gonadotropin-releasing hormone analogue medication" using "Gonadotropin-releasing hormone analogue medication Grouping Value Set (2.16.840.1.113883.3.526.3.1316)"
            </li>
            <li>
               "Medication, Active: Tamoxifen or Aromatase Inhibitor Therapy" using "Tamoxifen or Aromatase Inhibitor Therapy Grouping Value Set (2.16.840.1.113883.3.526.3.1315)"
            </li>
            <li>
               "Medication, Allergy: Tamoxifen or Aromatase Inhibitor Therapy" using "Tamoxifen or Aromatase Inhibitor Therapy Grouping Value Set (2.16.840.1.113883.3.526.3.1315)"
            </li>
            <li>
               "Medication, Intolerance: Tamoxifen or Aromatase Inhibitor Therapy" using "Tamoxifen or Aromatase Inhibitor Therapy Grouping Value Set (2.16.840.1.113883.3.526.3.1315)"
            </li>
            <li>
               "Medication, Order: Tamoxifen or Aromatase Inhibitor Therapy" using "Tamoxifen or Aromatase Inhibitor Therapy Grouping Value Set (2.16.840.1.113883.3.526.3.1315)"
            </li>
            <li>
               "Medication, Order not done: Medical Reason" using "Medical Reason Grouping Value Set (2.16.840.1.113883.3.526.3.1007)"
            </li>
            <li>
               "Medication, Order not done: Patient Reason" using "Patient Reason Grouping Value Set (2.16.840.1.113883.3.526.3.1008)"
            </li>
            <li>
               "Medication, Order not done: System Reason" using "System Reason Grouping Value Set (2.16.840.1.113883.3.526.3.1009)"
            </li>
            <li>
               "Patient Characteristic Birthdate: birth date" using "birth date LOINC Value Set (2.16.840.1.113883.3.560.100.4)"
            </li>
            <li>
               "Patient Characteristic Clinical Trial Participant: Clinical Trial Participant" using "Clinical Trial Participant Grouping Value Set (2.16.840.1.113883.3.526.3.1125)"
            </li>
            <li>
               "Patient Characteristic Sex: Female" using "Female Administrative Sex Value Set (2.16.840.1.113883.3.560.100.2)"
            </li>
            <li>
               "Procedure, Performed: Bilateral Oophorectomy" using "Bilateral Oophorectomy Grouping Value Set (2.16.840.1.113883.3.526.3.471)"
            </li>
            <li>
               "Procedure, Performed: Chemotherapy" using "Chemotherapy Grouping Value Set (2.16.840.1.113883.3.526.3.485)"
            </li>
            <li>
               "Procedure, Performed: Clinical Staging Procedure" using "Clinical Staging Procedure Grouping Value Set (2.16.840.1.113883.3.526.3.1098)"
            </li>
            <li>
               "Procedure, Performed: Radiation Therapy II" using "Radiation Therapy II Grouping Value Set (2.16.840.1.113883.3.526.3.1339)"
            </li>
            <li>
               Attribute: "Result: Breast Distant Metastasis Status M0" using "Breast Distant Metastasis Status M0 Grouping Value Set  (2.16.840.1.113883.3.526.3.1302)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Primary Tumor Size T0" using "Breast Cancer Primary Tumor Size T0 Grouping Value Set  (2.16.840.1.113883.3.526.3.1304)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Primary Tumor Size T1" using "Breast Cancer Primary Tumor Size T1 Grouping Value Set  (2.16.840.1.113883.3.526.3.1305)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Primary Tumor Size T1a" using "Breast Cancer Primary Tumor Size T1a Grouping Value Set  (2.16.840.1.113883.3.526.3.1164)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Primary Tumor Size T1b" using "Breast Cancer Primary Tumor Size T1b Grouping Value Set  (2.16.840.1.113883.3.526.3.1270)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Primary Tumor Size T1c" using "Breast Cancer Primary Tumor Size T1c Grouping Value Set  (2.16.840.1.113883.3.526.3.1306)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Primary Tumor Size T1mi" using "Breast Cancer Primary Tumor Size T1mi Grouping Value Set  (2.16.840.1.113883.3.526.3.1197)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Regional Lymph Node Status N1" using "Breast Cancer Regional Lymph Node Status N1 Grouping Value Set  (2.16.840.1.113883.3.526.3.1329)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Regional Lymph Node Status pN1a" using "Breast Cancer Regional Lymph Node Status pN1a Grouping Value Set  (2.16.840.1.113883.3.526.3.1311)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Regional Lymph Node Status pN1b" using "Breast Cancer Regional Lymph Node Status pN1b Grouping Value Set  (2.16.840.1.113883.3.526.3.1330)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Regional Lymph Node Status pN1c" using "Breast Cancer Regional Lymph Node Status pN1c Grouping Value Set  (2.16.840.1.113883.3.526.3.1331)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Regional Lymph Node Status pN1mi" using "Breast Cancer Regional Lymph Node Status pN1mi Grouping Value Set  (2.16.840.1.113883.3.526.3.1312)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Regional Lymph Node Status N2" using "Breast Cancer Regional Lymph Node Status N2 Grouping Value Set  (2.16.840.1.113883.3.526.3.1313)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Regional Lymph Node Status N3" using "Breast Cancer Regional Lymph Node Status N3 Grouping Value Set  (2.16.840.1.113883.3.526.3.1314)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Primary Tumor Size T2" using "Breast Cancer Primary Tumor Size T2 Grouping Value Set  (2.16.840.1.113883.3.526.3.1307)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Primary Tumor Size T3" using "Breast Cancer Primary Tumor Size T3 Grouping Value Set  (2.16.840.1.113883.3.526.3.1308)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Primary Tumor Size T4" using "Breast Cancer Primary Tumor Size T4 Grouping Value Set  (2.16.840.1.113883.3.526.3.1309)"
            </li>
            <li>
               Attribute: "Result: Breast Cancer Regional Lymph Node Status N0" using "Breast Cancer Regional Lymph Node Status N0 Grouping Value Set  (2.16.840.1.113883.3.526.3.1310)"
            </li>
         </ul>
         
      </div>
      <h3><a name="d2530824e4254" href="#toc">Reporting Stratification</a></h3>
      <div>
         
         <ul>
            <li>None</li>
         </ul>
         
      </div>
      <h3><a name="d2530824e4275" href="#toc">Supplemental Data Elements</a></h3>
      <div>
         
         <ul>
            <li>
               "Patient Characteristic Ethnicity: Ethnicity" using "Ethnicity CDC Value Set (2.16.840.1.114222.4.11.837)"
            </li>
            <li>
               "Patient Characteristic Payer: Payer" using "Payer Source of Payment Typology Value Set (2.16.840.1.114222.4.11.3591)"
            </li>
            <li>
               "Patient Characteristic Race: Race" using "Race CDC Value Set (2.16.840.1.114222.4.11.836)"
            </li>
            <li>
               "Patient Characteristic Sex: ONC Administrative Sex" using "ONC Administrative Sex Administrative Sex Value Set (2.16.840.1.113762.1.4.1)"
            </li>
         </ul>
         
      </div><br><hr align="left" color="teal" size="2" width="80%"><br><table class="header_table">
         <tbody>
            <tr>
               <td width="20%" bgcolor="#656565" style="background-color:#656565"><span class="td_label">Measure Set</span></td>
               <td colspan="3" width="80%">
                  <div style="width:660px;overflow-x:hidden;overflow-y:auto;word-wrap:break-word">None</div>
               </td>
            </tr>
         </tbody>
      </table>
   </body>
</html>